{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:23:08Z","timestamp":1779200588429,"version":"3.51.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the clinical outcomes of dydrogesterone (DYG) and medroxyprogesterone (MPA) in the progestin-primed ovarian stimulation (PPOS) protocol for patients with poor ovarian response (POR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This was a retrospective cohort study. Women with POR who underwent IVF\/ICSI at the Reproductive Center of Third Affiliated Hospital of Zhengzhou University between January 2020 and January 2021 were included. The primary outcome measure of our study was the number of oocytes retrieved. The secondary outcome measures in the present study were the number of 2PN, number of available embryos, oocyte retrieval rate, fertilization rate, viable embryo rate per oocyte retrieved, cancellation rate and pregnancy outcomes of the first embryo transfer cycle, including the biochemical pregnancy, clinical pregnancy and miscarriage rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 118 women underwent hMG +DYG protocols, and 692 women who underwent hMG +MPA met the Bologna criteria for POR. After baseline characteristics were balanced using the PSM model, 118 hMG +DYG protocols were matched to 118 hMG +MPA protocols, and the baseline characteristics were comparable between the two groups. The numbers of oocytes retrieved, 2PN, and available embryos and the oocyte retrieval rate, fertilization rate, viable embryo rate per oocyte retrieved and cancellation rate of the hMG+DYG and hMG+MPA protocols were comparable. Altogether, 66 women in the hMG+DYG group and 87 women in the hMG+MPA group underwent first embryo transfers. In the hMG+DYG group, 81.8% (54\/66) of the patients underwent cleavage embryo transfers; similarly, 79.3% (69\/87) of patients in the hMG+MPA group had cleavage embryo transfers (P=0.70).The biochemical pregnancy rate of the hMG+DYG group was 42.4%, and this was comparable to the rate in the hMG+DYG group, at 34.5% (P=0.32). The clinical pregnancy rates were similar between the two groups (36.4% <jats:italic>vs.<\/jats:italic> 31.0%, P=0.49), and there was no significant difference in the rate of miscarriage between the two groups (12.5% <jats:italic>vs.<\/jats:italic> 29.6%, P=0.14).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For women with POR, the clinical outcome of the hMG + DYG group was similar to that of the hMG + MPA group, indicating that both combinations can be useful options for PPOS protocols.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.708704","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:45:11Z","timestamp":1632530711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of Dydrogesterone and Medroxyprogesterone in the Progestin-Primed Ovarian Stimulation Protocol for Patients With Poor Ovarian Response"],"prefix":"10.3389","volume":"12","author":[{"given":"Junwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingze","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingnan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clinbiochem.2018.03.012","article-title":"Fertility and Infertility: Definition and Epidemiology","volume":"62","author":"Vander Borght","year":"2018","journal-title":"Clin Biochem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoz044","article-title":"Survey on ART and IUI: Legislation, Regulation, Funding and Registries in European Countries: The European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE)","volume":"2020","author":"Calhaz-Jorge","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00197","article-title":"New Twists in Ovarian Stimulation and Their Practical Implications","volume":"6","author":"Pirtea","year":"2019","journal-title":"Front Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.fertnstert.2011.09.048","article-title":"A Systematic Review of Randomized Trials for the Treatment of Poor Ovarian Responders: Is There Any Light at the End of the Tunnel","volume":"96","author":"Polyzos","year":"2011","journal-title":"Fertil Steril"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone Acetate is an Effective Oral Alternative for Preventing Premature Luteinizing Hormone Surges in Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/endo-92-5-1496","article-title":"Blockade by Progesterone of Estrogen-Induced LH and FSH Release in the Rhesus Monkey","volume":"92","author":"Dierschke","year":"1973","journal-title":"Endocrinology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1038\/s41598-017-08805-1","article-title":"Hypothalamic Effects of Progesterone on Regulation of the Pulsatile and Surge Release of Luteinising Hormone in Female Rats","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00796","article-title":"Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in Vitro Fertilization Treatment: A Randomized Controlled Trial","volume":"10","author":"Chen","year":"2019","journal-title":"Front Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002939","article-title":"Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and Hmg in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12958-017-0291-0","article-title":"Controlled Ovulation of the Dominant Follicle Using Progestin in Minimal Stimulation in Poor Responders","volume":"15","author":"Chen","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2011.02.043","article-title":"Selectivity and Potency of the Retroprogesterone Dydrogesterone in Vitro","volume":"76","author":". Ri\u017ener","year":"2011","journal-title":"Steroids"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex367","article-title":"New Application of Dydrogesterone as a Part of a Progestin-Primed Ovarian Stimulation Protocol for IVF: A Randomized Controlled Trial Including 516 First IVF\/ICSI Cycles","volume":"33","author":"Yu","year":"2018","journal-title":"Hum Reprod"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s230129","article-title":"Progestin-Primed Ovarian Stimulation With Dydrogesterone Versus Medroxyprogesterone Acetate in Women With Polycystic Ovarian Syndrome for in Vitro Fertilization: A Retrospective Cohort Study","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Design Dev Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE Consensus on the Definition of \u2018Poor Response\u2019 to Ovarian Stimulation for in Vitro Fertilization: The Bologna Criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The International Glossary on Infertility and Fertility Care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and Pharmacology of Progestins","volume":"61","author":"Schindler","year":"2008","journal-title":"Maturitas"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.07.1068","article-title":"Dual Trigger for Final Oocyte Maturation Improves the Oocyte Retrieval Rate of Suboptimal Responders to Gonadotropin-Releasing Hormone Agonist","volume":"106","author":"Lu","year":"2016","journal-title":"Fertil Steril"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh668","article-title":"Gnrh Antagonist Versus Long Gnrh Agonist Protocol in Poor Responders Undergoing IVF: A Randomized Controlled Trial","volume":"20","author":"Cheung","year":"2005","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00767","article-title":"Flexible Low-Dose Gnrh Antagonist Protocol Is Effective in Patients With Sufficient Ovarian Reserve in IVF","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.fertnstert.2014.04.010","article-title":"Diminished Ovarian Reserve is the Predominant Risk Factor for Gonadotropin-Releasing Hormone Antagonist Failure Resulting in Breakthrough Luteinizing Hormone Surges in In Vitro Fertilization Cycles","volume":"102","author":"Reichman","year":"2014","journal-title":"Fertil Steril"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.7.1490","article-title":"Treatment With the Gonadotrophin-Releasing Hormone Antagonist Ganirelix in Women Undergoing Ovarian Stimulation With Recombinant Follicle Stimulating Hormone is Effective, Safe and Convenient: Results of a Controlled, Randomized, Multicentre Trial","volume":"15","author":"Borm","year":"2000","journal-title":"Eur Orgalutran Study Group Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jogoh.2018.10.008","article-title":"Progestin-Primed Ovarian Stimulation is a Feasible Method for Poor Ovarian Responders Undergoing in IVF\/ICSI Compared to a Gnrh Antagonist Protocol: A Retrospective Study","volume":"48","author":"Huang","year":"2019","journal-title":"J Gynecol obstetrics Hum Reprod"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2019.101661","article-title":"Ovulation Induction With High Progesterone Levels may be More Suitable for Elderly Patients With Low Ovarian Response","volume":"50","author":"Mu","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.708704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:45:13Z","timestamp":1632530713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.708704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":23,"alternative-id":["10.3389\/fendo.2021.708704"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.708704","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"article-number":"708704"}}